Protocol I6T- MC-AMBP (a)  
 
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderate -to-Severe Plaque Psoriasis  
 [STUDY_ID_REMOVED]  Approval Date: 09- Aug-2018 
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63250] of Mirikizumab on the 
Pharmacokinetics of Cytochrome P450 Substrates in 
Patients with Moderate -to-Severe Plaque Psoriasis
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_57957] d in the clinical investigation of 
mirikizumab (LY3074828 ), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOI A) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries .  
Mirikizumab (LY3074828)
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Clinical Pharmacology Protocol Ele ctronically Signed and Approved by [CONTACT_11007] : 
27June 2018 .
Amendm ent (a) Electronically Signed and Approved by [CONTACT_57968] .
Approval Date: 09-Aug-2018 GMT
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63251] ivities....................................................................................................... 11
3. Introduction ...................................................................................................................... 18
3.1. Study  Rati onale ............................................................................................................ 18
3.2. Background .................................................................................................................. 18
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_63252] yle and/or Dietary Requirements ......................................................................... 33
6.3.1. Meals and Dietary  Restri ctions............................................................................. 33
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 34
6.3.3. Activity................................................................................................................ 34
6.4. Screen Failures ............................................................................................................. 34
7. Treatment .......................................................................................................................... 35
7.1. Treatment Administered ............................................................................................... 35
7.1.1. Packaging and Labeling ....................................................................................... 36
7.2. Method of Treatment Assignment ................................................................................ 36
7.2.1. Selection and Timing o f Doses ............................................................................. 36
7.3. Blinding ....................................................................................................................... 36
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 3
LY30748287.4. Dose Modi fication........................................................................................................ 36
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_63253] to Follow -up............................................................................................ 42
9. Study  Assessments and Procedures ................................................................................... 43
9.1. Efficacy Assessments ................................................................................................... 43
9.2. Adverse Events ............................................................................................................ 43
9.2.1. Serious Adverse Events ........................................................................................ 44
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 45
[IP_ADDRESS]. Adverse Event Monitoring with Systemat ic 
Quest ionnaires ................................................................................................ 45
[IP_ADDRESS].1. Columbia -Suicide Severit y Scale .............................................................. 45
[IP_ADDRESS].2. Quick Inventory  of Depressive Symptom atology-Self 
Report (16 Items) ...................................................................................... 46
9.2.2. Com plaint Handling ............................................................................................. 46
9.3. Treatment of Overdose .................................................................................................46
9.4. Safety........................................................................................................................... 47
9.4.1. Laboratory  Tests .................................................................................................. 47
9.4.2. Vital Signs ........................................................................................................... 47
[IP_ADDRESS]. Hypertensio n.................................................................................................. 47
9.4.3. Electrocardiograms .............................................................................................. 47
9.4.4. Immunogenicit y Assessments .............................................................................. 48
9.4.5. Safety Moni toring ................................................................................................ 48
[IP_ADDRESS]. Hepati c Safet y................................................................................................ 48
9.5. Pharmacokinet ics......................................................................................................... 49
9.5.1. Bioanalysis ........................................................................................................... 49
9.6. Pharmacodynamics ...................................................................................................... 49
9.7. Genet ics....................................................................................................................... 49
9.8. Biomarkers ................................................................................................................... 50
9.9. Heal th Economics ........................................................................................................ 50
10. Statistical Considerations and Data Analysis ..................................................................... 51
10.1. Sample Si ze Determinat ion.......................................................................................... 51
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63254] ics.......................................................................... 52
10.3. Statistical Analyses ...................................................................................................... 52
10.3.1. Pharmacokinet ic Analyses .................................................................................... 52
[IP_ADDRESS]. Pharmacokinet ic Parameter Estimat ion........................................................... 52
[IP_ADDRESS]. Pharmacokinet ic Statistical Inference ............................................................. 53
[IP_ADDRESS]. Pharmacokinet ic Exploratory Analyses ........................................................... 53
10.3.2. Safety Analyses .................................................................................................... 53
[IP_ADDRESS]. Clinical Evaluation of Safet y.......................................................................... 53
[IP_ADDRESS]. Statistical Evaluat ion of Safet y....................................................................... 54
10.3.3. Immunogenicit y Analyses .................................................................................... 54
10.3.4. Exploratory  Analyses ........................................................................................... 54
[IP_ADDRESS]. Efficacy Assessments ..................................................................................... 54
[IP_ADDRESS]. Biomarker Analyses ....................................................................................... 54
10.3.5. Interim Analyses .................................................................................................. 54
11. References ........................................................................................................................ 55
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63255] ives and Endpo ints....................................................................... 21
Table AMBP.3. Excluded Classes of Conco mitant Medi cations or Cl asses wi th 
Restricted Use ........................................................................................ 38
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63256] of Figures
Figure Page
Figure AMBP.1. Illustrati on of  study  design for Protocol I6T -MC-AMBP. ....................... 23
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63257] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 57
Appendix 2. Clinical Laboratory  Tests ........................................................................ 60
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 61
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 64
Appendix 5. Blood Sam pling Summary ...................................................................... 65
Appendix 6. Protocol  Amendment I6T -MC-AMBP(a) Summary Evaluat ion of 
the Effect of Mirikizumab on the Pharmacokinet ics of Cy tochrom e 
P450 Substrates in Patients with Moderate -to-Severe Plaque 
Psori asis.................................................................................................66
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 8
LY30748281.Protocol Synopsis
Title of Study:
Evaluatio n of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with 
Moderate -to-Severe Plaque Psoriasis
Rationale :  
Psoriasis is a chronic inflammatory skin disease in w hich elevated levels of proinflammatory cytokines may be
observed.  Chronic inflammation can, in theory, lead to disease -drug interactions by [CONTACT_57969] P450 (CYP) enzymes, thereby [CONTACT_57970].  
Therefore , treatment of psoriasis with biological products that reduce inflammation could result in changes in CYP 
activity .
Mirikizumab is ananti-interleukin (IL)-[ADDRESS_63258] a pathogenic role.  This study seeks to 
determine whether mirikizumab affects CYP activity in patients with psoriasis by [CONTACT_57971] g a “probe cocktail” approach, 
whereby [CONTACT_57972] ( PK)of CYP3A, CYP2C9, CYP2D6, CYP2C19, and CYP1A2 substrates 
midazolam, warfarin, dextromethorphan, omeprazole, and caffeine, respectively, will be evaluated before and after 
multiple mirikizumab doses are administered to patients with moderate -to-severe psoriasis.
Objective s/Endpoints:
Objectives Endpoints
Primary
To assess the effects of multiple doses of
mirikizumab on the PK of a drug cocktail of CYP 
substrates in patients with moderate -to-severe 
psoriasis .Ratio of geometric least squares means for Cmaxand 
AUC(0 -∞) of parent drug between each CYP 
substrate administered alone and in combination with 
mirikizumab .  
Secondary
To evaluate the tolerability of mirikizumab in patients 
with moderate -to-severe psoriasis.
To determine the PK of metabolites where 
appropriate.Incidence of TEAEs .
Ratio of geometric least squares means for the MR of 
AUC( 0-∞) metabolite :AUC( 0-∞) parent , as 
appropriate, between CYP substrate administered 
alone and in combination with mirikizumab.
Abbreviations:  AUC (0-∞) = area under the concentration versus time curve from zero to infinity ; Cmax=maximum 
observed drug concent ration;CYP = cytochrome P450; MR = metabolic ratio; PK = pharmacokinetics ; 
TEAE =treatment -emergent adverse event .
Summary of Study Design :  
Study I6T -MC -AMBP is a Phase 1, multicenter, 2 -period, fixed -sequence, open -label study to assess the effects of
multiple doses of mirikizumab on the PK of a drug cocktail of CYP substrates (midazolam, warfarin, 
dextromethorphan, omeprazole, and caffeine) in patients with moderate -to-severe psoriasis.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 9
LY3074828Blood sampling for assessment of PK of the CYP substrates (and me tabolites, as appropriate) ,inflammatory 
biomarkers, and mirikizumab PK and immunogenicity will be collected at prespecified visits.  Efficacy will be 
evaluated using static Physician ’sGlobal Assessment (sPGA), Psoriasis Area Severity Index (PASI), and pe rcentage 
of body surface area (BSA) assessments at prespecified visits.  Safety will be monitored throughout the study by 
[CONTACT_57973] ( AEs), clinical laboratory parameters, vital signs, physical examination, Quick Inventory 
of Depressive Sy mptomatology-Self Report (16 items) (QIDS -SR16), Columbia -Suicide Severity Rating Scale 
(C-SSRS) and Lilly Self -Harm Supplement responses, and electrocardiograms .
Treatment Arms and Planned Duration for Individual Patient s:
Each patient will be administere d:
2 oral doses (1 dose in each period) of dru g cocktail containing :  1mg midazolam, 10mg warfarin, 10mg 
vitamin K,30mg dextromethorphan, 20mg omeprazole, 100mg caffeine
5 subcutaneous (SC) doses of 250mg mirikizumab once every 4 weeks in pe riod 2
Planned duration for each patient:
Screening visit:  within 28 days prior to enrollment
Period 1: 6days; single dose of drug cocktail
Period 2: 120days; SCdoses of mirikizumab once ever y 4weeks for 16 weeks beginning Day 1 of Period 2, 
single dose of drug cocktail will be given 3 days ( within 48to 96 hours )after the final mirikizumab dose
Follow -upvisit:  approximately 24 day s after final PKsample is collected in Period 2
Number of Patients :  
Approximately 30patients will be enrolled with the assumption that 21 evaluable patients complete the study .  
Statistical Analysis:
Pharmacokinetics :  The PKparameter estimates for midazolam and 1
’-hydroxy midazolam, S -warfarin, 
dextromethorphan and dextrorphan, omeprazole and [ADDRESS_63259] treatments.  For the primary analysis, log -transformed area under the concentration versus time curve from 
zero to infinity (AUC[0 -∞]) and maximum observed drug concentration (Cmax) estimates will be evaluated in a
linear mixed-effects analysis of variance model with a fixed effect for treatment and a random effect for patient.  
The treatment differences will be back -transformed to present ratios of geometric least squares means and the 
corresponding 90% confidence intervals (CIs) .  The area under the concentration versus time curve from time zero 
to the last time point with a measurable concentration (AUC [0-tlast])and metabolic ratios will also be analyzed using 
this method.   The time of maximum observed drug conce ntration (tmax) will be analyzed using a Wilcoxon signed 
rank test.  Estimates of the median difference based on the observed medians, 90% CI, and p-values will be 
calculated.   Mirikizumab concentrations will be listed and summarized using descriptive stat istics.
Safety :  All AEs will be listed and,if the frequency of events allows, will be summarized using descriptive 
methodology.   The incidence of symptoms for each treatment will be presented by [CONTACT_57974].  Each symptom will be classified by [CONTACT_57975].   Any study  treatment -related serious AEs will be reported.   Clinical chemistry and 
hematology data, vital signs, C -SSRS scores, Lilly Self-Harm Supplement responses ,and QIDS -SR16 scores will be 
listed and summarized using standard descriptive statistics.  Urinalysis data will be listed.  Electrocardiograms and 
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 10
LY3074828physical examinations will be performed for safety monitoring purposes and will not be presented.  Additional 
analy sis will be performed if warranted upon review of the data.
Immunogenicity :  The frequency and percentage of patients with preexisting antidrugantibodies ( ADAs) and with 
treatment -emergent ADA ( TE ADA+ )to mirikizum ab will be listed and summarized.  The frequency of neutralizing 
antibodies will also be tabulated for TEADA+ patients.   The relationship between the presence of antibodies and the 
PK parameters and other response s, including safety and efficacy to miriki zumab, may be assessed.
Efficacy Assessments :  The PASI scores, sPGA responses, and percent BSA evaluation results will be listed and 
summarized.  The proportion of patients who achieved sPGA (0, 1) and sPGA (0), and PASI 75, PASI 90, and PASI 
100 (at leas t a 75 %, 90%, and 100% improvement from baseline in PASI score, respectively) will be summarized 
over time using descriptive statistics.  The change from baseline in percent BSA will also be summarized over time 
using descriptive statistics.
Inflammato ry Biomarkers :  Concentrations of IL-19and change from baseline will be listed and quantifiable 
concentrations will be summarized by [CONTACT_3148] .
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 11
LY30748282.Schedule of A ctivities
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 12
LY3074828Study Schedule Protocol I6T-MC -AMBP –Period [ADDRESS_63260] X
Vital Signs ( Sitting Blood Pressure and Pulse Rate) X X X
Clinical Laboratory Tests e X X X X
Pregnancy Test f X X
Physical Examination/Medical Assessment g X X X
12-Lead ECG X X
C-SSRS X X X X X
Self-Harm Supplement Form X X X X X
Self-Harm Follow -up Form h X X X X X
PASI X X
sPGA X X
% BSA Assessment X X
Review of AEs i X
Review Concomitant Medications X
Other Samples
Pharmacogenetic Sample Predose
hsCRPX X
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 13
LY3074828Screening Baseline
Procedure D -28to -2 D -1 D 1 D 2 D 3 D 4 D 5
Drug Administration
Drug Cocktail Administration X
PK Sample sj,k
(hours)
Midazolam and 1 ’-hydroxy midazolam Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 24
S-Warfarin Predose, 1, 2, 4, 6, 8, 10 24 48 72 96
Dextromethorphan and D extrorphan Predose, 1, 2, 4, 6, 8, 10 24 48 72
Omeprazole and 5-hydroxyomeprazole Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 24 48
Caffeine and Paraxanthine Predos e, 0.5, 1, 2, 3, 4, 6, 8, 12 24 48
Abbreviations:  AE = adverse event; BSA = body surface area; CRU = clinical research unit; C -SSRS =Columbia -Suicide Severity Rating Scale; D =Day; 
ECG =electrocardiogram; hsCRP = high sensitivity C-reactive protein; PASI =Psoriasis Area Severity Index; PK =pharmacokinetic; [COMPANY_003] = purified protein 
derivative; QIDS -SR16 =Quick Inventory of Depressive Symptomatology -Self Report (16 items); s PGA =static Physicians Global Assessment; 
TB=tuberculosis.
aPatients will be admitted at least [ADDRESS_63261](s) include [COMPANY_003], QuantiFERON ®-TB Gold, and T -SPOT ®, one of which should be used .
dA chest x-ray will be taken at screening unless one has been obtained within the last 6 months (provided the x -ray and/or report are available for review) .  The 
x-ray may be taken after the initial screening visit but before Day -1.
eScreening samples tested at a local laboratory, all other clinical laboratory test samples tested at a central labor atory.  Additional samples for coagulation 
parameters (
Appendix 2 ) may  be collected and tested at a local laboratory at the discretion of the inves tigator.  
fSerum pregnancy test to be performed at screening for all females .  Serum o r urine pregnancy test willbe performed locally at all other times for females of 
childbearing potential. Additional tests may be performed at the discretion of the i nvestigator.
gOne complete physical examination (excluding pelvic, rectal, and breast examinations) will be performed at screening.  All other medical assessments 
throughout the study should include a symptom directed physical as well as examination of heart, lungs, abdomen, and visual e xamination of the skin.
hRequired if triggered by [CONTACT_47584] -Harm Supplement Form per instructions (see Section [IP_ADDRESS].1 ).
iIf an AE of injection site reaction is reported, then the investigator will complete a supplemental injection site reaction f orm.
jSample times are relative to administration of the drug cocktail.  Separate blood samples will be collected for each of the co cktail drugs (caffeine, omeprazole, 
warfarin, dextromethorphan, and midazolam).
kSpecified times are approximate and actual times will be recorded.  Actual sampling time should not exceed acceptable windows indicated in Table AMBP. 1.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 14
LY3074828Table AMBP. 1. Acceptable Sampling Windows forPeriods 1 and 2
Nominal Sample Time Acceptable Sampling Window
Before study treatment administration (predose) Within 60 minutes before dosing
0.5 to 2 hours after study treatment dose ± 5 minutes
3 to 6 hours after study treatment dose ± 10 minutes
8 to 12 hours after study treatment dose ± 20 minutes
24 to 72 hours after study treatment dose ± 30 minutes
>72 hours after study treatment dose ± 2 hours
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 15
LY3074828Study Schedule Protocol I6T-MC -AMBP –Period 2
Note:  There will be 3 to 7 days between Period 1 Day 5andPeriod 2 Da y 1.
Period 2 FU/ED
Week 1 Week 4 Week 8 Week 12 Week 16 Week 17 Week 20
Procedure D 1 D 29 D 57 D 85 D 113 D 115 D 116 D 117 D 118 D 119 D 120 D 144
Visit Window ±2days ±2 days ±2 days ±1 day ± 1day ±1 day ±1day m±1day m±1day m±1day m±[ADDRESS_63262] d Predose Predose Predose Predose Predose X X
Medical Assessment e Predose Predose X X
12-Lead ECG Predose X
Clinical Laboratory Tests fPredose Predose Predose X X X X
Vital Signs (Sitting Blood 
Pressure and Pulse Rate)Predose Predose Predose Predose Predose X Predose X X
C-SSRS Predose Predose Predose Predose Predose X X X X X
Self-Harm Supplement 
FormPredose Predose Predose Predose Predose X X X X X
Self-Harm Follow -up 
Form gPredose Predose Predose Predose Predose X X X X X
QIDS -SR16 Predose Predose Predose
Urine Drug S creen X
Ethanol Breath Test X
Efficacy Asse ssments
PASI Predose X X X X Predose
sPGA Predose X X X X Predose
% BSA Assessment Predose X X X X Predose
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 16
LY3074828Period 2 FU/ED
Week 1 Week 4 Week 8 Week 12 Week 16 Week 17 Week 20
Procedure D 1 D 29 D 57 D 85 D 113 D 115 D 116 D 117 D 118 D 119 D 120 D 144
Visit Window ±2days ±2 days ±2 days ±1 day ± 1day ±1 day ±1day m±1day m±1day m±1day m±4 days
Other Samp lesh
Explo ratory  Inflammatory  
Biomarker sPredose Predose Predose Predose Predose Predose
IL-19 Predose Predose Predose Predose Predose Predose
hsCRP Predose Predose Predose Predose Predose X X
Mirikizumab 
Immunogenicity iPredose Predose Predose Predose X
Drug Administration
250 mg Mirikizumab SC X X X X X
Drug Cocktail X j
PK Samples (hours)
Mirikizumab h Predose Predose Predose Predose Predose Predose X
Midazolam and 
1’-hydroxy midazolam k,lPredose, 0.5, 1, 
2, 3, 4, 6, 8, 1224
S-Warfarin k,l Predose, 1, 2, 
4, 6, 8, 1024 48 72 96
Dextromethorphan and 
Dextrorphan k,lPredose, 1, 2, 
4, 6, 8, 1024 48 72
Omeprazole and 
5-hydroxy omeprazole k,lPredose, 0.5, 1, 
2, 3, 4, 6, 8, 1224 48
Caffeine and 
Paraxanthine k,lPredos e, 0.5, 1, 
2, 3, 4, 6, 8, 1224 48
Abbreviations:  AE = adverse event; BSA = body surface area; CRU = clinical research unit; C -SSRS =Columbia -Suicide Severity Rating Scale; D =Day; 
ECG =electrocardiogram; ED = early discontinuation; FU = Follow -up; hsCRP = high sensitivity C- reactive pr otein; IL = interleukin; PASI =Psoriasis Area 
Severity  Index; PK =pharmacokinetic; QIDS -SR16 =Quick Inventory of Depressive Symptomatology -Self Report (16 items); SC = subcutaneous; 
sPGA =static Physicians Global Assessment .
aPatients will be admitted at least [ADDRESS_63263] ion is reported, then the investigator will complete a supplemental injection site reaction form.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63264] willbe performed locally for females of childbearing potential. Additional tests may be performed at the discretion of the 
investigator.
eMedical assessment includes a symptom directed physical as well as examination of heart, lungs, abdomen, and visual examination of the skin.
fClinical laboratory samples tested at a central laboratory.  Additional samples for coagulation p arameters ( Appendix 2 ) may be collected and tested at a local 
laborato ry at the discretion of the investigator.  
gRequired if triggered by [CONTACT_47584]-Harm Supplement Form per instructions (see Section [IP_ADDRESS].1 ).
hSample times are relative to that day’s mirikizumab dose .  
iAny unscheduled immunogenicity samples should be collected with a time -matched sample for mirikizumab concentration analysis .
jDrug cocktail will be administered approximately 3 days (within 48to 96 hours )after the final mirikizumab dose.
kSample times are relative to administration of the drug cocktail.  Separate blood samples will be collected for each of the cocktail drugs (caffeine, o meprazole, 
warfarin, dextromethorphan, and midazolam).
lSpecified times are approximate and actual times will be recorded.  Actual sampling time should not exceed acceptable windows indicated in Table AMBP. 1.
mStudy days are relative to the day of drug cocktail administration.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63265] ions by [CONTACT_57976] n and activit y of som e cytochrome P450 (CYP) enzymes, 
thereby [CONTACT_57970] (Wang et al. 2014).  Therefore,
treatm ent of psoriasis wit h bio logical products that reduce inflammat ion could resul t in changes 
in CYP activit y.
Mirikizumab is an ant i-interleukin (IL) -[ADDRESS_63266] a patho genic role.  This study  seeks to determine whether mirikizumab affects CYP activit y 
in patients with psoriasis by [CONTACT_2329] a “probe cocktail” approach, whereby  [CONTACT_57977] 
(PK) of CYP3A, CYP2C9, CYP2D6, CYP2C19, and CYP1A2 substrates midazo lam, warfa rin, 
dextrom ethorphan, omeprazole, and caffeine, respectively, will be evaluated before and after 
multiple mirikizumab doses are administered to patients with moderate -to-severe psoriasis.
3.2. Background
Mirikizumab is a humanized IgG4-variant monoclonal ant ibody  that binds with high affinit y and 
specificit y to IL -23, a naturally occurring proinflammatory cytokine crit ically invo lved in the 
maintenance and amplification of T helper ( Th)17 cells .  Th17 cell s play a central rol e in the 
pathogenesis of mult iple autoimmune and chronic inflammatory  diseases, and neutralizat ion of 
IL-23 using mirikizumab results in clinical improvement .
Results fro m Study  I6T-MC-AMAE (Study  AMAE) , in which healthy subjects received 250-mg
mirikizumab doses in prefilled syringes [ PFS], 
showed that the m aximum  observed drug 
concentration (C max) of mirikizumab wasobserved 3days postdose and the h alf-lifeassociated 
with the terminal rate constant in nonco mpart mental analysis (t1/2)was 11.6 days.  Preliminary 
analyses o f data in patients with ulcerative colit is (UC) and psoriasis indicate that the PK of
mirikizumab in these patients is similar to healthy subjects, and there are no patient factors that 
have a clinically  relevan t impact on PK.
3.3. Benefit/Risk Assessment
As of 02 February  2018, there were approximately 819 participants in studies of mirikizumab 
(including 245 patients with psoriasis, 248 patients with UC, 85 patients with Crohn’s disease , 
and 241 healthy subjects) exposed to either placebo or mirikizumab at single doses ranging fro m 
5 to1200 mg and mult iple doses up to a maximum of 1000 mg intravenous ly(IV) once every  
4weeks for 12 weeks and up to 300 m g subcutaneous ( SC)once every  8weeks for 16 weeks .  
Although the mirikizumab SC dose regimen o f 250 m g once every  4weeks has not y et been 
administered in humans, the drug exposure in this study is expected to be less than that of 
1000 mg IV once every  4weeks for 12weeks , which has been well tolerated.   
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 19
LY3074828In com pleted or ongoing clinical pharmaco logy studi es, nodose-related safet y or tol erability 
issues were observed.  Inj ection site pain, of short duration (usually hours), has been reported .  
Data from  completed StudyAMAE and preliminary  data f rom Study  I6T-MC-AMAL
(Study AMAL) showed that most inject ion site reactions were mild or moderate in severit yand 
primarily related to mild ery thema and pain , with severe inject ion site pain reported in 2% of 
inject ion site reactions in the [ADDRESS_63267] formulat ion grou p.  Approximately 6% of subjects 
reported diarrhea fo llowing administration of placebo and both the [ADDRESS_63268] and 250- mg 
reference SC formulat ions of mirikizumab in Studies I6T-MC-AMAA, I6T-JE-AMAD, AMAL, 
and AMAE .
As of 02 February  2018, Phase 2 Study  I6T-MC-AMAF (Study  AMAF) examining SC 
mirikizumab doses in patients with moderate -to-severe plaque psoriasis was st ill ongo ing.  Inthe 
induct ion peri od (the first 16 weeks) of this study , pati ents were randomized to 1 of the 
4treatm ent arms (30 m g mirikizumab, 100 m g mirikizumab, 300mg mirikizumab, or placebo) 
and received correspondent doses at Week 0 and Week 8 .  At Week 16, patients entered the 
maintenance period (88 weeks) where they were dosed as needed (no higher than 300 mg and no 
more frequent tha n Q8W) based on the Psoriasis Area Severit y Index (PASI) responses. To date, 
evaluat ion of the unblinded safet y data fro m Study AMAF hasnot revealed any dose -related 
safet y or tol erabilit y issues.  At the 32- week interim analysis, reported treatm ent-emergent 
adverse event s (TEAEs )were generally mild or moderate in severit y and the m ost comm on 
TEAE was viral upper respi[INVESTIGATOR_39738].  One death attributed to lung cancer has been
reported during the maintenance period; however, the death was not c onsidered rel ated to study  
treatm ent.  Three patients had a serious adverse event ( SAE )in the placebo -controlled induct ion 
period:2 patients had suicidal ideat ion and 1 patient had both increased alanine 
aminotransferase (ALT )and increased aspartate aminotransferase (AST) . One patient had an 
SAE (endocarditis bacterial) in the maintenance period .  Two patients discontinued treatment 
early  due to an adverse event ( AE)(maternal exposure during pregnancy  and suicidal ideat ion 
[an SAE]) in the placebo -controlled induct ion period; 4patients discont inued treatment early due 
to an AE (m aternal  exposure during pregnancy, psori atic arthropathy, rash, and bacteri al 
endocardit is [an SAE ]) in the maintenance period .  
To assess the nonclinical toxicit yof mirikizumab and establish a margin of safet y for clinical 
studi es, 4-week and 6 -month general toxicit y studies in healt hy, norm al cyno molgus mo nkeys 
were conducted for the evaluat ion of immunotoxicit y, toxicokinet ics, safet y pharmaco logy (as 
part of th e 4-week study ), and fertilit y (as part of the 6 -month study ). The weekly administration 
ofmirikizumab to cyno molgus monkeys resulted in no adverse mirikizumab -related findings at 
doses of 0 mg/kg (vehicle), 1 and 30 mg/kg (SC), or 100 mg/kg (IV) for 4 weeks, or 0, 10, and 
100 m g/kg (SC) for [ADDRESS_63269] -level in the 4- week and 6 -month studi es provi ded 52 -and 22 -fold 
margin o f safet y, respectively, relat ive to the predicted human exposure of the proposed 
mirikizumab dose in the present study (250 m g administered SC every  4week s).
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63270] ivity following blocking IL -23 in
autoimmune/inflammatory  diseases including psoriasis, the favorable safet y and PK profile of
mirikizumab, and the init ial clinical act ivity observed for mirikizumab in pat ients with psori asis,
the potenti al benefi ts of participat ing in Study AM BPare expected to outweigh the potential
risks.
More informat ion about the known and expected benefits, risks, SAEs ,and reasonably 
anticipated AEs of mirikizumab are to be found in the Invest igator’s Brochure (IB).  
Inform ation about the known and expected benefit s, risks, SAEs, and reasonably anticipated AEs 
for each of the cocktail drugs are to be found in each drug ’s respective Package Insert.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63271] ives and endpo ints of the study .
TableAMBP .2. Objectives and Endpoints
Objectives Endpoints
Primary
To assess the effects of multiple doses of 
mirikizumab on the PK of a drug cocktail of CYP 
substrates in patients with moderate -to-severe 
psoriasis.Ratio of geometric least squares means for Cmaxand 
AUC (0-∞) of parent drug between each CYP 
substrate administered alone and in combination with 
mirikizumab.
Secondary
To evaluate the tolerability of mirikizumab in patients 
with moderate -to-severe psoriasis .
To determine the PK of metabolites where 
appropriate.Incidence of TEAEs.
Ratio of geometric least squares means forthe MR of 
AUC( 0-∞) metabolite :AUC( 0-∞) parent , as 
appropriate, between CYP substrate administered 
alone and in combination with mirikizumab .
Exploratory
To explore the effects of mirikizumab on the PK of a 
drug cocktail of CYP substrates in the subgroups of 
patients with moderate -to-severe psoriasis who 
respond to mirikizumab treatment at Week 16and 
those who do not respond.
To evaluate the effects of mirikizumab treatment over
time on inflammatory biomarker concentrations in 
patients with moderate -to-severe psoriasis.Ratio of geometric least squares means between each 
CYP substrate administered alone and in combination 
with mirikizumab for C maxand AUC(0 -∞) of parent 
drug in responders and nonresponders.
Change f rom baseline in inflammatory biomarker 
concentrations over time during 16weeks of 
mirikizumab treatment.
Abbreviations:  AUC (0-∞) = area under the concentration versus time curve from zero to infinity ; Cmax=maximum 
observed drug concentration ;CYP = cytochrome P450; MR = metabolic ratio; PK = pharmacokinetics ; 
TEAE =treatment -emergent adverse event .
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 22
LY30748285.Study  Design
5.1. OverallDesign
This is a Phase 1, m ulticenter, 2-period, fixed -sequence, open -label study  to asse ss the effects of 
multiple doses of mirikizumab on the PK of a drug cocktail o f CYP substrates (midazolam, 
warfarin, dextromethorphan, omeprazo le, and caffeine) in pat ients with moderate -to-severe 
psori asis.  Figure AMBP.1illustrates the study  design.
Blood sam pling for assessment of PK of the CYP substrates (and metabo lites, as appropri ate), 
inflammatory  biomarkers, and mirikizumab PK and immunogenicit y will be co llected at 
prespecified visits.  Efficacy will be evaluated using static Physicians Global Assessment 
(sPGA) , PASI , and percentage of body  surface area (BSA) assessments at prespecified visit s.  
Safety will be m onitored throughout the study  by [CONTACT_57978], clinical laboratory  
param eters, vi tal signs, physical examinat ion, Qui ck Invento ry of Depressive 
Symptom atology-Self Report (16 i tems) (QIDS -SR16), Columbia -Suicide Severit y Rating Scale 
(C-SSRS), Lilly Self -Harm  Supplement ,and electrocardiogra ms (ECGs).
Study  governance considerations are described in detail in Appendix 3 .
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 23
LY3074828Abbreviations :  BSA = body surface area ; PASI = Psoriasis Area Severity Index ; PK = pharmacokinetic ;sPGA =static Physicians Global Assessment.
Note:  In Period 2, d rug cocktail will be administered 48 to 96 hours after the final mirikizumab dose .  
Figure AMBP. 1. Illustration of study design for Protocol I6T -MC-AMBP.-1 Day 1 2
Inpatient period3 4 5Drug cocktail 
administrationPeriod 1
X  
□   116±1 118±1119±1
[ZIP_CODE]±1
Drug Cocktail PK samplingDrug cocktail 
administration
144±4
20Follow -up 
1
129±1
457±1
885±1
[ZIP_CODE]±1
16Period 2
250 mg mirikizumab administrationDrug Cocktail PK samplingScreening 
Day -29to 
Day -2
X
□ X
□ X
□ X
□ X
□ Day
Week115±1 117±1
□ X
Mirikizumab immunogenicity and PK samples 
PASI, sPGA , and % BSA assessment and Inflammatory biomarker samples
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 24
LY30748285.2. Number of Participants
Approximately  30patients will be enrolled with the assumption that 21 evaluable patients 
complete the study .  For purposes of this study, a pati ent com pletes the study  when all scheduled 
blood sam ples for drug cocktail PK analyses shown in the Schedule of Activit ies (Secti on 2) 
have b een collected in Period 2.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last patient.
5.4. Scientific Rationale for Study Design
This is an open -label study , which is an appropriate approach for the primary  PK object ives of 
the study .  The fixed
-sequence design is used due to the long half- life o f mirikizumab.
This study  will be conducted in patients with moderate -to-severe plaque psori asis as this is one 
of the pati ent popul ationsfor whom  mirikizumab treatm ent is indicated; conduct ing the study in 
this popul ation allows the assessment of the effec t of mirikizumab on CYP enzymes expressed in 
the disease state before and after treatment .
Regulatory  agencies recommend conduct ing a clinical drug interaction study using a drug 
cocktail approach when interactions wit h mu
ltiple CYPs are invest igated (EMA 2012; 
FDA 2017; PMDA 2013).  Drugs used in such a cocktail should be select ive for the specific 
CYP enzymes, should not interact with each other, and ult imately should be safe when 
administered.  One such drug cocktail is a modified 5+1 Cooperstown cocktai l which includes 
midazo lam (CYP3A), warfarin (CYP2C9), dextromethorphan (CYP2D6), omeprazo le 
(CYP2C19), caffeine (CYP1A2), and vitamin K (to counter the anticoagulant effect of warfarin), 
and has been administered in previous studies (Goh et al .2010; Ma e t al.2006).  The drug 
cocktail will be administered in Period 1, prior to init iation of miri
kizumab dosing, and again on 
Day 116 ([ADDRESS_63272] mi rikizumab dose) of Period2, when steady -state concentrations of 
mirikizumab shoul d be achieved.   
The total required blood volume of 590mL is considered acceptable given that blood samples 
are taken during the course of the study  which has a minimum duration of approximately  
20weeks.
5.5. Justification for Dose
Drug cocktail containing 1 mg midazolam, 10 mg warfarin (+ [ADDRESS_63273] of warfarin ), [ADDRESS_63274] been used conc omitantly in previous clinical studies .  
The 1 -mg oral dose of midazo la
m used f or this study  is lower than the 5 -mg oral  dose that has 
been used in so me published cocktail studies.  Use of 1 mg benefit s pati ent safet y since this dose 
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63275] anned 
for the treatm ent inducti on peri od in the Phase 3 Study  AMAK and ar e based primarily on 
analyses o f interim PK, safet y,and efficacy  data f rom the Phase 2 Study  AMAF, safet y data 
from other clinical studies evaluat ing mirikizumab , and nonclinical safet y data. 
In Peri od 2, the drug cocktail will be administered on Day  116 ([ADDRESS_63276] mirikizumab 
dose) , which is approximately at C maxof mirikizumab concentration at steady  state .
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63277] ing 
condi tions will  be docum ented.
Screening may occur up to 28 d ays prior to enrollment.  Patients who are not enrolled within 
28days of screening may  be subjected to an addit ional medical assessment and/or clinical 
measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment a nd enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible for inclusio n in the study  only  if they meet all of the following criteria at 
screening and/or enrollment:
Type of Patient and Disease Characteristics
[1] present with chronic plaque psoriasis based on the investigator -confirmed 
diagnosis of chronic psoriasis vulgaris for at least [ADDRESS_63278] admissio n to the clinical 
research unit ( CRU ):
A.plaque psori asis invo lving ≥10% BSA ,
B.absolutePASI score ≥12 in affected skin , and
C.sPGA score of ≥3
[2] candidate for systemic therapy  and/or phototherapy
Patient Characteristics
[3] malesor females
A.male patients:  nomale contracep tion requi red except i n compliance wit h 
specific local government study  requi rement
B.female patients:
womennot of childbearing potential may participate and include those 
who are:
i.infertile due to surgi cal sterilizat ion (hysterectomy, bilateral 
oophorectom y, or tubal  ligation), congenital ano maly such as 
mullerian agenesis
OR
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 27
LY3074828ii.postmenopausal , defined as:
a.awom an at l east [ADDRESS_63279] uterus, not on 
horm one therapy , who has had either:
1.
cessat ionof menses for at l east [ADDRESS_63280] 6 months o f spontaneous amenorrhea with a fo llicle 
stimulat ing hormone >40 mIU/mL
OR
b.awom an [ADDRESS_63281] 55 y ears of age with a diagnosis of menopause 
prior to starting hormone replacement therapy
womenof childbearing potential:
i.musttest negative for pregnancy prior to init iation of treatment as 
indicated by  a negat ive serum pregnancy test a t the screening visit 
followed by a negat ive pregnancy test within [ADDRESS_63282] inence ( eg, calendar, ovulat ion, 
symptothermal, post -ovulation methods), decl aration of abst inence just 
for the durati on of  a trial, and wi thdrawal are not acce ptable m ethods 
of contracepti on.
OR
mustuse [ADDRESS_63283] ive methods o f contracepti on (such as male or female 
condoms with spermicide, diaphragms with spermicide ,or 
cervical sponges) will be used .  The patient m ay choose to use a 
doubl e-barrier method of contraception .  Barrier protection 
methods without concomitant use of a spermicide are not a 
reliable or acceptable method.  Thus, each barrier method must 
include use of a spermicide .  It should be noted that the use of 
male and female condo ms as a double -barri er method is not 
considered acceptable due to the high failure r ate when these 
methods are combined.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63284] ive (less than 1% failure rate) method of contraception 
(such as co mbinat ion oral  contraceptives, implanted 
contraceptives ,or intrauterine devices).
[4] areat least 18 y ears of age at the time of screening
[5] haveadequate organ funct ion, including:
A.hematol ogic:  
i.absoluteneutrophil count 1.5 × 10 9/L (1.5× 10 3/µL or 1.5GI/L )
ii.plateletcount 100 × 10 9/L (100 × 10 3/µL or 100 GI/L )
iii. hemoglobin level  10.0 g/dL ( 100 g/L )
iv. lymphocy tecount >500 cells/µL (>0.50 × 10 3/µL or >0.50 GI/L )
v.totalwhite blood cell count 3.0 × 10 9/L (3.0 ×103/µL or 3.0GI/L )
B.chemistry :
i.serum creat inine ≤2×the upper limit of normal (ULN )
ii.ALT ≤2×ULN
iii. AST ≤2×ULN
iv. totalbilirubin level (TBL) <1.5×ULN (patients with Gilbert’s 
syndro me must have serum direct bilirubin <1.5 mg/dL or 
<25.7 µmol/L)
v.alkaline phosphatase (ALP) <1.5 ×ULN
(Note:  The tests for AST and ALT may be repeated once within a week if 
the init ial respons e exceeds this limit, and the repeat value may be accepted 
if it meets this cri terion.  Other l aboratory  tests shoul d not be repeated 
unless there is a technical error or clinical reasons to believe a result may be 
erroneous, and requires approval by  [CONTACT_941] L illy-designated m edical mo nitor.)
[6] havevenous access sufficient to allow for blood sampling as per the protocol
[7] arereliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[8] areable and willing to give signed informed consent
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 29
LY30748286.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:   
Medical Conditions
[9] havean abnorm ality in the 12 -lead ECG that, in the opi[INVESTIGATOR_1649] o f the 
investigator, increases the risks associated with participat ing in the study
[10] havean unstable or uncontrolled illness, including ,but not limited to ,a 
cerebro -cardiovascular, respi[INVESTIGATOR_696] , hepa tic, renal, gastrointestinal, endocrine, 
hematol ogic, or neurol ogic disease or abnormal laboratory  values at screening 
that, in the opi[INVESTIGATOR_3078] n of the invest igator, would potent ially affect pati ent safety  
within the study  or of  interfering with the interpretat ion of data
[11] presence of significant uncontrolled neuropsychiatric disorder or judged 
at-risk of suicide in the opi[INVESTIGATOR_3078] n of the invest igator
OR
scores a 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS -SR16 at 
screening
OR
a “yes” answer to Question 4 (Act ive Suicidal Ideation with Some Intent to 
Act, Without Specific Plan) or Question 5 (Active Suicidal Ideat ion with 
Specific Plan and Intent) on the “Suicidal Ideation” portion of the C -SSRS at 
screening or at first admissio n to the CRU
OR
a
“yes”answer to any  of the suici de-related behaviors (actual attempt, 
interrupted attem pt, aborted attempt, prepa ratory act or behavior) on the 
“Suicidal Behavior” portion of the C -SSRS and the ideation or behavior 
occurred within [ADDRESS_63285] admissio n to the CRU
[12] have human immunodeficiency virus ( HIV)/acqu ired immune deficiency 
syndro meor test posit ive for HIV antibodies at screening
[13] havehepat itis C or test posit ive for hepatit is C v irus (HCV) at screening, 
defined as:  positive result for hepatit is C ant ibody  and posi tive confirmatory  
HCV RNA test .  Patients in sustained viro logic response after HCV therapy , 
and pat ients who have spontaneously cleared HCV infect ion can be included 
in this study .
[14] havehepat itis B or test posit ive for hepatit is B virus ( HBV) at screening, 
defined as :  
A. positivefor hepat itis B surface ant igen
OR
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63286] less of anti-hepat itis B surface ant ibody status
[15] havehad serious, opportunist ic, or chronic/recurring infect ion within 
3months pri or to screening.  Examples include, but are not limited to, 
infect ions requiring IVantibiotics, hospi[INVESTIGATOR_3094], or prol onged treatm ent.
[16] havereceived a systemic (including oral) ant
i-infective agent for an infect ion 
within [ADDRESS_63287] admissio n to the CRU
[17] havehad, according to the invest igator, clinically significant herpes zoster 
within 3 m onths prior to screening
[18] haveevidence of active or latent tuberculosis ( TB),as documented by [CONTACT_57979], chest x -rays (posteri or anteri or), and TB 
testing:  lack o f TB will be demonstrated by  [CONTACT_5640] a negat ive purified protein 
derivat ive ([COMPANY_003]) test (defined as a skin indurat ion <5 mm at 48 to 72 hours, 
regardl ess of Bacillus Calmette -Guerin [BCG ]or other vaccinat ion history ) or 
a negat ive (not indeterminate) Quant iFERON -TB Gol d test or T -SPOT.   If the 
Quant iFERON -TB Gol d test or T-SPOT is indeterminate, one repeat test is 
permitted .  The choice to perform a [COMPANY_003], QuantiFERON -TB Gold test, or 
T-SPOT will be made by [CONTACT_57980].  The Quant iFERON -TB Gol d test can only be used in 
countri es where i t is licensed, and the use of this test is dependent on previous 
treatm ent(s).  This test may not be suitable if previous treatment(s) produce 
significant immunosuppressio n.Patients who test posit ive for latent TB at 
screening may be rescreened following appropri ate treatm ent (see
Secti on6.4).
[19] havereceived a BCG vaccinat ion within 12 months or received live vaccine(s) 
(including attenua ted live vaccines) within [ADDRESS_63288] admissio n to the 
CRU or intend to receive either during the study
[20] haveactive or history  of lympho ma, leukemia, or any  malignancy .The
following c onditions are not excl usionary: successfully treated basal cell skin 
carcino ma, squamous cell skin carcino ma, or cervical carcino ma in situ, with 
no evidence of recurrence or metastatic disease within the [ADDRESS_63289] 
admissio n to the CRU .
[21] haveany other skin condit ions (excluding plaque psoriasis) that would affect 
interpretati on of  the resul ts (including, but not limited to, scleroderma, 
eczema, drug -induced psoriasis, guttate psoriasis, pustular psoriasis, 
parapsoriasis, or cutaneous manifestations of other autoimmune diseases such 
as systemic lupus ery thematosus )
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 31
LY3074828[22] havea known allergy  or hypersensit ivity to any  component of the 
mirikizumab product form ulationor the drug cocktail that would pose an 
unacceptable risk to the patient if participat ing in this study
[23] arewom en who are breastfeeding or plan to breastfeed during study
[24] havedonated bl ood of  >[ADDRESS_63290] admissio n to the 
CRU, or intend to donate blood during the course of the study
[25] hadany major surgery  within [ADDRESS_63291] igator in 
consultation wit h Lilly or its designee, would pose an unacceptable risk to the 
patient
[26] havea history  of unco mpensated heart failure, fluid overload, or myocardial  
infarction , or evidence of new -onset i schemic heart disease or other serious 
cardi ac disease, wi thin [ADDRESS_63292] admissio n to the CRU
[27] haveuncontrolled arteri al hypertensio n characte rized by  a systolic bl ood 
pressure (BP) >160 mm Hg or diastolic BP >100 mm Hg
(Note:  Determined by 2 consecut ive elevated readings.  If an init ial BP 
reading exceeds this limit, the BP may  be repeated once after the patient has 
rested sitting for ≥10 minu tes.  If the repeat value is less than the criterion 
limits, the second value may  be accepted.)
[28] haveany other condi tion that precludes the patient fro m following and 
completing the protocol, in the opi[INVESTIGATOR_3078] n of the investigator
[29] clinically significant increased prothrombin time at screening
Prior/Concomitant Therapy
[30] have received systemic nonbio logic psoriasis therapy  (including, but not 
limited to, oral psoralen and ultravio let A [PUVA] light therapy; cyclosporine; 
corticosteroi ds; methotrexate; oral retino ids; apremilast; tofacit inib; 
mycopheno late mofetil; thioguanine; hydroxyurea; si rolimus; tacrolimus; 
azathioprine; lefludimide; fumaric acid derivat ives; or 1,25- dihydroxy vitamin 
D3 and analogues) or phototherapy  (including eit her oral  and topi [INVESTIGATOR_57958] , ultraviolet B, excimer laser, or self -treatm ent wi th tanning 
booths or therapeutic sunbathing) within [ADDRESS_63293] 
administration of the drug cocktail
[31] have received topi [INVESTIGATOR_57959]
(including, but not limited to, corticosteroids [ mild or least potent topi[INVESTIGATOR_57960] f or use limited to the face, axilla, or genitalia ], 
crisaborol e, anthralin, calcipotri ene, topi [INVESTIGATOR_26445] D derivat ives, retino ids, 
tazarotene, pim ecrolimus, tacrolimus, emo llients and other nonprescription 
topi[INVESTIGATOR_57961], >3% salicylic acid, alpha -or beta -hydroxy
acids, or m edicated shampoos [ eg,those that contain >3% salicylic acid, 
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 32
LY3074828corticosteroi ds, coal  tar, or vi tamin D3 analo gues]) wi thin [ADDRESS_63294] administrati on of  the drug cocktail
[32] havereceived anti- Tum or Necrosis Factor targeting bio logics wi thin [ADDRESS_63295] administrati on of the drug cocktail
[33] haveprevi ous exposure to any  biologic therapy  targeting IL -12/23 (p40 
subunit )or IL -23 (p19 subunit), eit her m arketed or invest igational, or 
exposure to other bio logical immunom odulating treatments
[34] areunable or unwilling to avoid excessive sun exposure or use of tanning 
booths for at least [ADDRESS_63296] admissio n to the CRU and during the 
study
[35] requiretreatm ent wi th inhibitors of CYP3A, CYP2C9, CYP2D6, CYP2C19, 
or CYP1A2 ;with inducers of CYP 3A or CYP1A2; or wi th rifampin (inducer 
of multiple CYPs) within [ADDRESS_63297] administration of the drug 
cocktail until Peri od2 Day  
120assessments are complete
[36] requiretreatm ent wi th substrates of CYP3A, CYP2C9, CYP2D6, CYP2C19, 
or CYP1A2 w ith narrow therapeutic indices within [ADDRESS_63298] igator and by [CONTACT_57981] (CRP) , or clinical pharmaco logist (CP), or 
designee
[37] requireongoing treatm ent with midazo lam, warfarin, dextromethorphan, 
omeprazo le, or caffeine ,or requi re treatm ent with a drug contraindicated with 
midazo lam, warfarin, dextromethorphan, omeprazole, or caffeine (per the 
prescribing label and Package Insert for each drug) within [ADDRESS_63299] administrati on of  the drug cocktail until Perio d2 Day 120assessments 
are com plete
Prior/Concurrent Clinical Study Experience
[38] arecurrently enrolled in a clinical study  involving an invest igational product 
or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study
[39] haveparticipated, wi thin the last [ADDRESS_63300] has a long 
half-life, 3 months or 5half-lives (whichever is longer) should have passed 
prior to screening.
[40] haveprevi ously  com pleted or wi thdrawn from  this study  or any  other study  
investigat ing mirikizumab
Study Restrictions
[41] areunwilling to comply with the dietary  requi rements/restri ctions during the 
study which incl ude:  
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63301] 
admin istrati on of  the drug cocktail unt il Period 2 Day  120 assessments are 
complete
[42] cannot avoid excessive sun exposure or use of tanning booths for a t least 
4weeks prior to first admissio n to the CRU and during the study
[43] arecurrently or have been smokers or users of tobacco or nicotine 
replacement products within [ADDRESS_63302] admissio
n to the CRU
[44] intendto consume caffeine -or xanthine -containing food or beverages (eg, tea, 
coffee, colas, and choco late) from 5 days pri or to each administration of the 
drug cocktail and until co llection of the 48- hour drug cocktail PK samples in 
each peri od
[45] havean average weekly  alcohol  intake that exceeds 21 units per week (males 
up to age 65) and 14 units per week (males over 65 and females), or are 
unwilling to stop alcoho l consumption for at least 24 hours prior to each visit 
to the CRU, and while resident in the CRU ( 1 uni t = 12 oz or 360 mL of beer; 
5 oz or 150 mL of wine; 1.[ADDRESS_63303] illed spi[INVESTIGATOR_2120] )
Other Exclusions
[46] have CYP2D6 genoty pe, if known, indicat ive of a poor m etabo lizer
[47] areinvest igativesite personnel  direct ly affiliated with this study  and thei r
immediate families.  Immediate family is defined as a spouse, biological or 
legal guardian , child ,or sibling .
[48] areLilly emplo yees or em ployees o f third-party  organizat ioninvolved with 
the study  who requi re exclusio n of their emplo yees
[49] areunsuitable for inclusio n in the study in the opi[INVESTIGATOR_3078] n of the investigator or 
sponsor for any  reason that m ay com promise the pati ent’s safet y or confound 
data interpretation
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , patients may  undergo m edical  assessments and review of compliance wit h 
requirements before continuing in the study .  
6.3.1. Meals and Dietary Restrictions
Patients will  be provi ded wi th standard m eals while resi dent in the CRU.  Patients sh ould not 
consume food fro m [ADDRESS_63304] adm inistrati on of  the drug cocktail (Day  1of 
Period 1) until the last drug coc ktail PK sample is collected in Period 2.  
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 34
LY30748286.3.2. Caffeine, Alcohol, and Tobacco
Patients are not allowed to consume caffeine -or xanthine -containing food or beverages from
5days priortoeach drug cocktail administration ( Period 1 Day 1and Period 2 Day 116) until 
collect ion of the [ADDRESS_63305] drug cocktail PK samples in Period 2.  
6.3.3. Activity
Patients will  be encouraged to m aintain thei r regular exercise; however, t hey shoul d not 
undertake vigorous or prolonged exercise within 48 hours prior to each CRU visit or while 
resident in the CRU.  
6.4. Screen Failures
Individuals may  be rescreened only 1 time for failure due to Exclusio n Cri teria [16] or [18].  
Patients who do not qualify at scre ening under Exclusio n Cri teria [16] ( recent systemic 
anti
-infective treatment ) may be rescreened (1 time) [ADDRESS_63306] posit ive for latent TB
(Excl usion Criteria [18])at screening may be rescreened (1 time) if they meet the fo llowing 
requi rements:
Have received at least [ADDRESS_63307] of care, and
Have no evidence of treatment hepatotoxicit y (ALT and AST l evels must remain 
≤2×ULN upon retesting of serum ALT and AST levels prior to fi rst dose )
Each time rescreening is performed ,the individual must sign a new informed consent form ( ICF
)
and will be assigned a new ident ification number.
Patients who have had previous screening chest radiography  and TB tests as per protocol within 
3monthsof their rescreening date of consent do not need to repeat these procedures but may  do 
so at the discretion of the invest igator .
Repeat testi ng to confirm laboratory  test resul ts will  not be consi dered rescreening.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63308] ivities (Section 2).  Detailed instructions for study treatment
administration will be provided by [CONTACT_1034]
.
Mirikizumab
Mirikizumab will be administered by [CONTACT_57982].  Each 250-mg mirikizumab dose will b e 
supplied as two
1-mL PFS.
Drug cocktail
The drug cocktail will contain midazo lam, warfarin (plus vitamin K), dextromethorphan, 
omeprazo le, and caffeine. Thecocktail drugs will be coadministered orally wit h approximately 
240 mL of room temperature water, in a sitting posit ion.Administration of each cocktail drug 
will be according to the respective instructions for use .  
Midazolam
The 1 -mg oral dose will be administered as 0.5mL of 2 -mg/mL commercially available 
midazo lam syrup .
Warfarin
The 10-mg oral doses will be administered as 2 × 5-mgtablets of  commercially  available
warfarin plus 2 × 5-mgtablets of commercially  available vitamin K.
Dextromethorphan
The 30- mg oral dose will be administered as 2 ×15-mgliquid gel capsules of commercially 
available dextrom ethorphan .
Omeprazole
The 20- mg oral dose will be administered as 1× 20-mgtabletof commercially  available
omeprazo le.
Caffeine
The 100- mg (caffeine base) oral dose will be administered as 10 mL of 20 -mg/mL commercially 
available caffeine citrate sol ution(with 10mg caffeine base per 1 mL so lution).
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63309] igator or designee is responsible for:
explaining the correct use of the investigational product s to the site personnel 
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection, and
returning all unused medication to Lilly  or its designee at the end of the study
Note : In some cases, sites may destroy  the m aterial  if, during the invest igativesite select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedures to dispose of clinical materials .  
7.1.1. Packaging and Labeling
Mirikizumab will be supplied by [CONTACT_57983] -use, so lution PFS.  The [ADDRESS_63310] will be labeled according to the country’s regulatory requirements .  
All invest igational products will be stored, inventoried, reconciled, and returned or destroy ed 
according to applicable regulat ions. 
7.2. Method of Treatm ent Assignment
This study  is not subject to randomizat ion.
7.2.1. Selection and Timing of Doses
All patients will receive the dose regimen as specified in the Schedule of Activit ies (Secti on 2).
The doses will be administered at approximately the same t imes on each day.  The actual t ime of 
all dose administrations will be recorded i n the patient ’s electronic case report form  (eCRF).
7.3. Blinding
This is an open -label study .
7.4. Dose Modification
Dose reductions or adjustments will not be allowed during this study .  
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 37
LY30748287.5. Preparation/Handling/Storage/Accountability
Mirikizumab shoul d be transported and stored in refrigerated condit ions of 2°C to 8°C (36°F to 
46°F).  D etailed instructions regarding supplies and preparation and handling of invest igational 
products will be provided by [CONTACT_456].
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained , as communicated by s ponsor, during transit for all invest igational product received 
and any  discrepancies are reported and resolved before use of the study  treatment .
Only participants enro lled in the study  may receive invest igational product or study  materials, 
and only  authori zed site staff may  supply  or administer invest igational product .All 
investigat ional products should be stored in a nenvironmentally controlled and mo nitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access limited 
to the invest igator and authorized site staff .
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record ma intenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
7.6. Treatment Compliance
The study  treatm entwill be administered at the clinical site, and documentation of treatment 
administration will occur at the site.
7.7. Concomitant Therapy
All concomitant m edicat ions taken during the study  must be recorded on the Concomitant 
Medicat ion eCRF.  Allpatientsshoul d maintain thei r usual  medicati on regimens for concomitant 
condi tions or di seases throughout the study  unless those m edicat ions are specifi cally excluded in 
the protocol.
Patients taking conco mitant m edicat ions should be on stable dosages at the time of baseline and 
shoul d remain at stabl e dosages throughout the study  unless changes need to be made because of 
AEs.  Addit ional systemic drugs a re to be avo ided during the study, unless required to treat AEs. 
If the need for concomitant medicat ion arisesfor an AE or for appropriate medical management 
(including the limited use of therapeut ic agents which, if used under treatment regimens other 
than for treating an AE or for appropriate medical management, might be considered psoriasis 
therapi [INVESTIGATOR_014]), inclusio n or continuat ion of the pati ent may be at the discret ion of the invest igator 
after consul tation wi th a Lilly CP or CRP .  Other medicat ions m ay be allowed if they are 
approved by  [CONTACT_3210] i ts desi gnee.
Use of nonlive ( killed, inactivated , or subunit ) vaccinat ions are allo wed for all patient s; however, 
their efficacy with conco mitant mirikizumab is unknown .  Use of live, atte nuated vaccines is 
prohibited.
Classes of therapi[INVESTIGATOR_57962] , or permi tted wi th use 
restri ctions, are specified in Table AMBP.3(also see the Exclusion Criteria [Section 6.2]).
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63311] DoseAllowed During StudyAllowed 
with 
RestrictionsConditions for Allowed Use
Treatment with midazolam, warfarin, 
dextromethorphan, omeprazole, or caffeineN
within 
14daysN
until final PK assessments 
are completeN
Drugs contraindicated with midazolam, 
warfarin, dextromethorphan, omeprazole, or 
caffeine (per the prescribing label and Package 
Insert for each drug)N
within 
14daysN
until final PK assessments 
are completeN
Known inhibitors of CYP3A, CYP2C9, 
CYP2D6, CYP2C19, or CYP1A2 ;inducers of 
CYP3A or CYP1A2 ;or rifampin (inducer of 
multiple CYPs)N
within 
14daysN
until final PK assessments 
are completeN
Known substrates of CYP3A, CYP2C9, 
CYP2D6, CYP2C19, or CYP1A2 with narrow 
therapeutic indicesN
within 
14daysN
until final PK assessments 
are completeY At the discretion of the investigator and by 
[CONTACT_57984] .
Topi[INVESTIGATOR_57963] n
(eg, corticosteroids , crisaborole, anthralin, 
vitamin D analogues, pi[INVESTIGATOR_031], retinoids, 
salicylvaseline, salicylic acid, lactic acid, 
tacrolimus, tar, urea, -hydroxy acids ,or fruit 
acids)N
within 
14daysN
until final PK assessments 
are completeN
Topi[INVESTIGATOR_57964], 
axilla, or genitaliaN
within 
2daysN
within [ADDRESS_63312] potent topi[INVESTIGATOR_57965], axilla, and/or 
genitalia, as needed.  
Photochemotherapy
(eg, PUVA)N
within 
4weeks N N
Phototherapy
(eg, UVA, UVB, excimer laser)N
within 
4weeks N N
Anti-TNF biological agents
(eg, etanercept, adalimumab, infliximab, 
certolizumab)N
within 
8weeksN N
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63313] DoseAllowed During StudyAllowed 
with 
RestrictionsConditions for Allowed Use
Anti-IL-17 biological agents
(eg, secukinumab , ixekizumab )N
within 
12weeksN N
Biological therapy targeting IL -12/23 or IL -23
(eg, briakinumab, ustekinumab )N N N
Biological immunomodulating agents
(eg, alefacept , efalizumab )N N N
Other systemic immunomodulating treatments
(eg, MTX, cyclosporine A, corticosteroids , 
cyclophosphamide)N
within 
4weeks N N
Systemic immunomodulating treatments 
(corticosteroids only)N N Y Limited use of systemic corticosteroids ONLY as 
needed for limited, short -term medical management 
of TEAE may be considered.  Such drug class might 
be considered psoriasis therapy if used under other 
regimens.  Limited use during TEAE management is 
considered to not be consistent with psoriasis 
therapy .
Systemic psoriasis therapi[INVESTIGATOR_014]
(eg, retinoids, fumarates, apremilast) N
within 
4weeks N N
BCG or live virus vaccinations  N N N
Any investigatio nal treatment N N N
Abbreviations:  BCG = Bacillus Calmette -Guerin ; CRP = clinical research physician; CYP = cytochrome P450; MTX = methotrexate; N = No; 
PK=pharmacokinetics; PUVA = psoralen and ultraviolet A; TEAE =treatment -emergent adverse event; TNF = tumor necrosis factor; UVA = ultraviolet A; 
UVB =ultraviolet B; Y =Yes.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63314] ion is not applicable to this study .
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63315] igator when a pat ient meets 1 of the fo llowing condit ions after consultation with the 
Lilly -designated m edical m onitor:
ALT orAST >5×ULN.
ALT or AST > 3×ULN sustained for more than 2 weeks .
ALT or AST >3 ×ULN and TBL >2×ULN orinternat ional norm alized rati o>1.5.
ALT or AST >3 ×ULN wit
h the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) .
ALP>3×ULN .
ALP >2.5×ULN and TBL >2 ×ULN .
ALP >2.5×ULN wi th the appearance of fat igue, nausea, vo miting, right quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) .
In addit ion, pati ents will  be discont inued fro m the investigat ional product in the fo llowing 
circumstances:
Total  white blood cell count <2000 cells/ L (<2.00 × 103/µL or <2.00 GI/L).
Lymphocy te count <500 cells/μL (<0.50 ×
103/µL or <0.50 GI/L).
Platelet coun t <50,000 cells/μL (<50 ×
103/µL or <50 GI/L) .  
Changes in BP (systolic BP at ≥160 mm Hg plus ≥2 0mmHg increase fro m baseline; 
and/or diastolic BP at ≥100 mm Hg plus ≥10mmHg increase fro m baseline) that do not 
respond fo llowing maximal  allowed interventi on (further expl anation in Sect ion9.4.2.1 )
.  
The patient beco mes pregnant.
It is recommended that the patient be assessed by  [CONTACT_57985] m study  treatm ent and the 
study  ifthe patient :
i. Scores a 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS- SR16 ;
OR
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63316] with or without a 
specific plan ( “yes”to Question4 or 5 on the “Suicidal Ideation” portion 
of the C -SSRS) ;
OR
iii. Develops s uicide -related behavi ors as recorded on the C -SSRS ;
OR
iv. Develops self -injuri ous behavi ors that woul d be classified as non -suicidal  
self-injuri ous behavior .
8.1.1. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ifies a pati ent who di d not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  CP/CRP and the invest igator to 
determine if the pat ient may  cont inue in the study .  If both agree i t is medically  appropriat e to 
continue, the invest igator must obtain documented approval fro m the Lilly CP/CRP to allow the 
inadvertent ly enro lled pat ient to conti nue in the study  with or wi thout continued treatment with 
investigat ional product.   
8.2. Discontinuation from the Study
Patients will  be discont inued in the fo llowing ci rcumstances:
Enrollment in any other clinical study  involving an invest igational product or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice
Invest igator Decisio n
othe invest igator decides that the patient should be discontinued from the study
oif the pat ient, for any  reason, requi res treatm ent with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
PatientDecision
othe patient requests to be withdrawn fro m the study .
8.3. Patients Lost to Follow -up
A pat ient will be considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_57986] a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_4179].
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63317] ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix [ADDRESS_63318] ivities (Secti on 2).  
The PASI is an accepted and comm only used primary e
ndpoin ttomeasure psori asis severi tyin 
clinical studi es(EMA 2004; Menter et al. 2008).  The PASI combines assessments of the extent 
of BSA involvement in4anatomica lregions (head, trunk, arms, and legs) and the severity of 
desquama tion(scaling) , erythema (redness) ,and plaque indura tion/ infiltration (thickness) in 
eachanatomical region, yielding an overall score of 0 for no psoriasis to 72 for severe disease 
(Fredri ksson and Pettersson 1978).  A clinically meaningful response is a PASI 75, which 
represents at least a 7 5% decrease (improvement) from the baseline PASI score.  Higher levels o f 
clearance (PASI 90), as well as complete resolut ion of psori asis (PASI 100), have beco me 
additional endpoints because of the increasing recognit ion of the associat ion of higher clear ance 
with greater heal th-related quali ty of life (Pui g 2015).
ThesPGA is the physician’s glo bal assessment of the pat ient’s psoriasis lesio ns evaluated at a 
given time po int (EMA 2004).  Pl aques are assessed for indurat ion, ery thema, and scaling, and 
an overall rat ing of psoriasis severit y is given using the anchors of clear (0), minimal (1), mild 
(2), m oderate (3), severe (4), or very  severe (5) .  
Percent BSA will be evaluated as the percent invo lvement of psoriasis on each pat ient’s BSA on 
a continuous scale fro m 0% (no invo lvement) to 100% (full invo lvement), where 1% 
corresponds to the size of the patient’s hand (including the palm, fingers, and thumb) (National 
Psori asis Foundat ion 2009 ).
9.2. Adverse Events
Invest igators are responsible for monitoring the safety  of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medica l care of pat ients during the study
.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63319] ,via eCRF ,the occurrence and nature of 
each p atient’s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  Addit ionally , site personnel will record any  change in the 
condi tion(s) and the occurrence and nature of any AEs.  
The inves tigator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment or a study  procedure, taking into account the disease, 
concomitant treatment ,or pathol ogies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the study  treatm ent (i e, drug cocktail, mirikizumab, or drug cocktail + mirikizumab) , study  
device, and/or study  procedure and the AE.
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
If a patient’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via eCRF.
If an AE of inject ion site react ionis reported, then the invest igator will complete asuppl emental  
inject ion site reaction form.  The inject ion site reaction form documents the presence of 
erythema, induration, pain (mild, m oderate, or severe) , pruri tus, and edem a.
9.2.1. Serious Adverse Event s
An SAE is any  AE from this study  that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital anomaly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_313] m ay jeopardi zethe pati ent or may  requi re intervent ion to prevent 
one of the other outcomes listed in the definit ion above
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 45
LY3074828when a condit ion related to the PFS necessitates medical or surgical intervention to 
precl ude ei ther perm anent impairment of a body  function or permanent damage to a body  
structure, the serious outcome of “required intervent ion” will be assigned
Study  sitepersonnel must alert the Lilly  CRP/CP, or i ts desi gnee, of  any SAE as soon as 
pract ically possible.
Addit ionally , study site personnel  must al ert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin [ADDRESS_63320] 
discontinued from and/or com pleted the study  (the patientsummary eCRF has been completed).  
However, if the invest igator learns of any SAE, including a d eath, at any  time after a patienthas 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .  
Pregnancy (maternal or paternal e xposure to investigat ional product ) does not meet the definit ion 
of an AE.  However, to fulfill regulatory  requi rements any pregnancy  should be reported 
following the SAE process to collect data on the outcome for both mother and fetus.
[IP_ADDRESS]. Suspected Unexpecte d Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator reports as related to invest igational product or procedure.  Lilly  
has procedures that will be f ollowed for the recording and expedited reporting of S[LOCATION_003]Rs that 
are consistent with global regulations and the associated detailed guidances.
[IP_ADDRESS]. Adverse Event Monitoring with Systematic Questionnaire
s
Before administering the C -SSRS or QIDS -SR16, study site personnel will question the patient 
about any  change in the preexist ing condit ion(s) and the occurrence and nature of any AEs.  
Nonserious AEs obtained through the questionnaires are recorded and ana lyzed separately.  Only 
serious AEs elic ited through the C -SSRS or QIDS -SR16 are to be recorded as AEs via eCRF and 
reported to Lilly  or its designee wi thin 24 hours as SAEs.
[IP_ADDRESS].1. Columbia -Suicide Severity Scale
The nonleading AE collect ion shoul d occur pri or to the collect ion of the C -SSRS. If a 
suicide-related event is discovered during the C -SSRS but was not captured during the 
nonleading AE collect ion, sites shoul d not change the AE form. If an event is serious or leads to 
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 46
LY3074828discontinuat ion, thi s is an excep tion where the SAE and/or AE leading to discont inuat ion should 
be included on the AE form and the process for reporti ng SAEs shoul d be fo llowed.
Suicide-related events (behavior and/or ideat ions) will be assessed and evaluated with the 
administration of th e C-SSRS ,Self-Harm  Supplement Form , and Self -Harm  Follow-up Form .  
The C -SSRS captures the occurrence, severit y, and f requency of suicidal ideat ion and/or 
behavior during the assessment period.  The scale includes suggested questions to solicit the ty pe 
of informat ion needed to determine if suicidal ideation and/or behavior occurred.  The Self -Harm  
Form sfocuson behaviors (suicidal and non -suicidal  self-harm ). If the number of behavioral 
events ident ified on the Self -Harm  Supplement Form is greater than zero, it will lead to the 
completion of the Self -Harm  Follow-up Form .  The Self -Harm  Follow-up Form  is a series of 
questions that provides a more detailed descript ion of the behavior cases .  The C -SSRS i s 
administered by  [CONTACT_57987] t rained healthcare professio nal with at least 1 y ear of pat ient 
care/clinical experience.  For this study , the scal e has been adapted (wi th permissio n from the 
scale authors) to include only  the porti on of  the scale that captures the occurrence of the 
11 pr eferred ideat ion and behavior categories.
[IP_ADDRESS].2. Quick Inventory of Depressive Symptomatology -Self Report (16 Items)
TheQIDS -SR16 is a self-administered, 16-item instrum ent intended to assess the existence and 
severit y of symptom s of depressio n as listed in the American Psychiatric Associat ion’s 
Diagnostic and Stati stical Manual of Mental Disorders, 5thEdition (APA
2013).  A patient is 
asked to consider each statement as it relates to the way  they  have fel t for the past 7 days.  There 
is a 4 -point scale for each item ranging from  0to3.  The 16 items corresponding to 9 depression 
domains are summed to give a single score ranging from 0 to 27
, with higher scores denoting 
greater symptom severit y.  The dom ains assessed by  [CONTACT_57988]:  (1) sad mood, (2)
concentration, (3) self -criticism , (4) suicidal  ideation, (5) interest, (6) energy/fat igue, (7) sleep 
disturbance (init ial, middle, and late inso mnia or hyperso mnia), (8) decrease/increase in 
appeti te/wei ght, and (9) psy chomotor agi tation/retardati on.
9.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studi esin order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients shoul d be instructed to con tact the invest igator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product or PFS so that the situation can be 
assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdos e of mirikizumab or the cocktail drugs is con sidered 
any dose higher than the assigned dose.  
In case of suspected mirikizumab overdose, hematology , chemistry , vital signs, and oxygen 
saturation should be monitored and supportive care provided as nec essary .  There i s no known 
antidote for mirikizumab .
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 47
LY3074828Refer to the P ackage Insert of each cocktail drug for informat ion on treatm ent of overdose.  
9.4. Safety
9.4.1. Laboratory Tests
For each patient, laboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).  
9.4.2. Vital Signs
For each patient, sitting vital signs ( BPand pulse rate )shoul d be measured after resting for at 
least 5minutes at times indicated in the Schedule of Act ivities (Secti on 2), and prior to blood 
sampling or administration of study  treatm ent.
Addit ional vital signs may be m easured during each study  period if warranted
.  Unscheduled 
orthostati c vital signs shoul d be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  If orthostatic measurements are required, patients should be supi[INVESTIGATOR_31146] [ADDRESS_63321] 2 minutes.
[IP_ADDRESS]. Hypertension
Patients who experience changes in BP (sy stolic BP at ≥160 mm Hg plus ≥20 mm Hg increase 
from baseline; and/or diastolic BP at ≥100 mm Hg plus ≥10 mm Hg increase fro m baseline) on 
2consecutive visit s are to receive intervention for the manage ment of hypertensio n.  Intervent ion 
may begin wit h lifestyle changes and could lead to the maximal  intervent ion of wit hholding the 
dose of invest igational product (see Section 8.1)and/or the introduction of ant ihypertensive 
agent(s) as medically  appropri ate.
9.4.3. Electrocardiograms
For each patient, a single 12-lead di gital ECG will  be collected according to the Schedule of 
Activities(Secti on 2).  Electrocardi ograms m ust be recorded before collecting any  blood 
samples .  Patients must be supi[INVESTIGATOR_17044] 5 to 10 minutes before ECG collection and 
remain supi[INVESTIGATOR_57966].  Electrocardiograms may be obtained at 
additional times,when deemed clinically necessary.   All ECGs recorded should be stored at the 
investigat ional site.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
patient is st ill present, to determine wh ether the patient meets entry  criteria at the rel evant visit(s) 
and for immediate patient management, should any clinically relevant findings be identified.  
If a clinically significant finding is ident ified (including, but not limited to ,changes in QT/Q Tc 
interval  from baseline) after enrollment, the investigator will determine if the patient can 
continue in the study .  The invest igator ,or qualified designee ,is responsible for determining if 
any change in pat ient management is needed ,and must document his/her review of the ECG 
printed at the time of collection.  Any clinically relevant finding sshoul d be reported as an AE.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63322] ivities (Secti on 2), venous blood samples 
will be co llected to determine ant ibody  producti on against mirikizumab .  
To interpret the results 
of immunogenicit y, a venous blood sample will be collected at the same t ime points to determine 
the serum  concentrati ons of  mirikizumab .  All sampl es for immunogenicit y shoul d be taken 
predose when applicable and possible.  In the event of drug hypersensit ivity react ions 
(imme diate or non -immediate) , additional samples will be co llected as close to the onset of the 
event as possible, at the resolut ion of the event, and [ADDRESS_63323] ion and handling of blood samples will be provided b y the sponsor.  The actual  date 
and 24 -hour cl ock time of each sampling will be recorded.   
Treatment -emergent ant idrug ant ibodies ( TE ADAs) are defined in Sect ion10.3.[ADDRESS_63324] scheduled assessment or discont inuat ion visit is increasing 
(com pared to previous measurements) or remains high (titer greater than 1:1000), addit ional 
samples may be taken until the titer reaches a plateau/decreases (if increasing) or remains the 
same/decreases (if high).  
Immunogenicit y will be assessed by  a validated assay  designed to detect antidrug ant ibodies 
(ADAs) in the presence o f the mirikizumab at a labor atory  approved by [CONTACT_456].  Antibodies 
may be further characterized and/or evaluated for their abilit y to neutralize the activit y of the 
mirikizumab.  
Samples will  be retained for a m aximum  of [ADDRESS_63325] patient visit, or for a shorter 
period if local  regulat ions and ethical review boards ( ERBs )allow, at a facilit y selected by  [CONTACT_103].  The duration allows the sponsor to respond to future regulatory  requests rel ated to the 
mirikizumab .  Any samples rem aining after 15 y ears will be des troyed.
9.4.5. Safety Monitoring
The Lilly CPor CRP /scientist will mo nitor safet y data throughout the course of the study .
Lilly will review SAEs wit hin time frames mandated by [CONTACT_17069].  The Lilly CPor 
CRP will periodically review the following data:
trends in safety  data
laboratory  analy tes
AEs
When appropriate, the Lilly CPor CRP will consult with the funct ionally  independent Gl obal 
Patient Safet y therapeutic area physician or clinical research scient ist.
[IP_ADDRESS]. Hepatic Safety
If a study  patient experiences elevated ALT ≥3×ULN, ALP ≥2×ULN , or el evated TBL
≥2×ULN, liver tests ( Appendix 4 ) shoul d be repeated wi thin [ADDRESS_63326] bilirubin , gamma- glutamyl  transferase, and creat inine kinase to confirm  the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63327] igator based on 
consultation wit h the Lilly CPor CRP .  Moni toring shoul d continue unt il levels norm alize and/or 
are return ingto approximate baseline levels .  
Addit ional safet y data should be co llected if 1or more of  the f ollowing condit ions occur :  
elevation of serum  ALT to ≥5×ULN on 2or more consecut ive blood tests
elevated serum TBL to ≥2×ULN (except for cases of known Gilbert’s syndrome)
elevation of serum  ALP to ≥2×ULN on 2 or more consecut ive blood tests 
patient discont inued fro m treatm ent due to a hepatic event or abnormalit y of liver tests
hepatic event considered to be anSAE
9.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities
(Secti on 2), separat e venous blood 
samples wil l be co llected to determine plasma concentrations of midazo lam and i ts metabo lite 
1’-hydroxymidazo lam, S-warfa rin, dextromethorphan and its metabo lite dextrorphan, 
omeprazo le and its metabo lite 5-hydroxy omeprazole, and caffeine and its metabolite 
paraxanthine.  Samples will also be co llected to determine serum  concentrati ons of  mirikizumab .  
Instructi ons for the c ollect ion and handling of blood samples will be provided by [CONTACT_456]
.  
The actual  date and [ADDRESS_63328] pati ent visi t for the study .  
9.6. Pharmacodynamic s
Not applicable .
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis asspecified in the Schedule o f 
Activities(Secti on 2), where local regulat ions allo w.  
Samples willnotbeused to conduct unspecified disease or p opulation genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
mirikizumab and to investi gate geneti c variants thought to pl ay a rol e in psori asis.  Assessment 
of variable response may include evaluation o f AEsor differences in efficacy.  
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63329] patient visit, or for a shorter 
period if local regulat ionsand/or ERBs impose shorter time limits , for the study  at a f acilit y 
selected by [CONTACT_47551] i ts desi gnee .  This retenti on peri od enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the devel opment of mirikizumab or after mirikizumab is co mmercially available.  
Molecular techno logies are expected to improve during the [ADDRESS_63330] ivities (Secti on 2) where local regulat ions allow.
Samples will  be used to m easure IL -
19.Samples are collected f or C-reactive protein and may 
also be used as an exploratory  biomarker.   Samples mayalso be used for research on the drug 
target ,disease process, variable response to mirikizum ab, pathways associated with psori asis, 
mechanism o f action of  mirikizumab , and/or research method ,or for validating diagnosti c tools 
or assay (s) related to psoriasis .  All samples will be coded with the patient number.  These 
samples and any data generated can be linked back to the patient only by [CONTACT_57989] l.  
Samples will  be retained for a m aximum  of [ADDRESS_63331] patient visit , or for a shorter 
period if local regulat ionsand/or ERBs impose shorter time limits ,at a facilit y selected by [CONTACT_57990] .  Thi s retenti on peri od enables use o fnew techno logies, response to regulatory  
questions, and invest igation of varia ble response that may  not be observed unt il later in the
develop ment of mirikizumab or after mirikizumab is co mmercial ly available.   
9.9. Health Economics
Thissection is not appli cable for this study .
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 51
LY307482810. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
Approximately  30patients will be enrolled with the assumption that 21 evaluable patients 
complete the study .
Midazolam
For midazo lam area under the concentration versus time curve ( AUC )and C max, the intrasubject 
variabilit y (coefficient of variat ion [CV])was estimated to be 16.1% and 26.4%, respectively 
(derived from a previous study ).  Based on this assum ption, 21 patients will provide a precisi on 
of 0.1 and 0.1 7 on a log- scale for AUC and C max, respectively.  This would result in a 90% 
probabilit y that the half -width of the 90% confidence interval ( CI)of the rati o of the geom etric 
means for AUC and Cmaxis no larger than 9.8% and 15.3%, respectively.  
Warfarin
For S -warfarin AUC and C max, the intrasubject variabilit y (CV) was est imated to be 7% and 8%, 
respectively  (Steinijans et al .1995).  Based on these estimates, 21 patients will provide a 
preci sion of 0.045 and 0.049 on a l og-scale for AUC and C max, respec tively.  This would result 
in a 90% probabilit y that the half -width of the 90% CI of the ratio of the geometric means for
AUC and C maxis no larger than 4.4% and 4.8%, respect ively.  
Dextromethorphan
For dextrom ethorphan AUC and C max, the intrasubject variabilit y (CV) was est imated to be 
33.5% and 32.1%, respectively (derived fro m a previous study ).  Based on these est imates, 
21patients will provide a precisi on of 0.206 and 0.197 on a l og-scale for AUC and C max, 
respectively .  This w ould resul t in a 90% probability  that the half -width of the 90% CI of the 
ratio of the geom etric means for AUC and C maxis no larger than 18.6% and 17.9%, respectively.  
Omeprazole
For om eprazo le AUC and C max, the intrasubject variabilit y (CV) was est imated to be 21.8% and 
29.8%, respectively  (HMA 2009 ).  Based on these assumpt ions, 21 patients will provide a 
preci sion of 0.135 and 0.184 on a l og-scale for AUC and C max, respectively.  This would result 
in a 90% probabilit y that the half -width of the 90% CI of the rati o of the geom etric means for
AUC and C maxis no larger than 12.6% and 16.8%, respectively.  
Caffeine
For caffeine AUC and C max, the intrasubject variabilit y (CV) was est imated to be 21.0% 
(Blanchard and Sawers 1983) and 23.4% (Turpault et al. 2009), respectively.  Based on these 
estimates, 21 patients will provide a precisi on of 0.13 and 0.148 on a log- scale for AUC and 
Cmax, respectively.  This would result in a 90% probabilit y that the half -width of the 90% CI of 
the rati o of the geom etric me ans is no l arger than 12.2% and 13.8%, respectively .  
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 52
LY307482810.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f patient di sposi tion will be provi ded at the end of the study .  
10.2.2. Study Participant Characteristics
The patient’s age, sex , race, wei ght, hei ght, body mass index , and other dem ographi c 
characterist ics will be recorded.  Baseline disease severit y (PASI , sPGA score , and percentage of 
BSA ), age of psori asis onset, and previous psoriasis therapy  typewill also be recorded and 
reported.
Patient characterist ics will be summarized and listed .  Summaries will include descript ive 
statist ics (mean, standard deviation, sample size, minimum, maximum, lower and upper 
quartiles) for the continuous parameters, and frequencies and percenta ges for the rem aining 
categori cal parameters.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee .
Pharmacokinet ic anal yses will be conducted on the full analysis set.  For drug cockta il PK, th e 
full analysis set incl udes all  data from  all pat ients receiving at least one dose of drug cocktail, 
with evaluable PK data, according to the treatment the patients actually received.  For 
mirikizumab PK, th e full analysis set includes all data f rom all pat ients receiving at least one 
dose of mirikizumab wi th evaluable PK data.   For patients with serum mirikizumab 
concentrations that are less than the drug exposure range expected after multiple doses , the drug 
cocktail PK resul ts for Period 2may be ex cluded from  the analysis and the rati onale will  be 
provi ded in the study  report.
Safety analyses will be conducted for all enr olled pati ents, w hether or not they  com pleted all  
protocol  requi rements.
Biomarker analyses will be conducted for all pat ients receiving at least one dose of mirikizumab 
with at least one postbaseline measurement in Period [ADDRESS_63332] -hoc analyses and inco mplete di sclosures of analyses.   
10.3.1. Pharmacokinetic Analyses
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for midazo lamand 1 ’-hydroxymidazo lam, S-warfarin, 
dextrom ethorphan and dextrorphan, omeprazo le and 5- hydroxyo meprazo le, and caffeine and 
paraxanthine will be calculated by  [CONTACT_57991].
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 53
LY3074828For midazo lamand 1 ’-hydroxymidazo lam, S-warfarin, dextromethorphan and dextrorphan, 
omeprazo le and 5 -hydroxy omeprazo le, and caffeine and paraxanthine, the primary parameters 
for analysis will be C max, AUC from zero to infinity  (AUC [0-∞]), and metabo lic ra tio (MR) .  
Metabo lic ratios will be calculated as AUC(0 -∞) metabolite/AUC(0 -∞) parent corrected for 
molecular weight.  Other noncompart mental parameters such as time of maximum observed drug 
concentration (t max), AUC from time zero to the last time point w ith a measurable concentration 
(AUC[[ADDRESS_63333]]), t1/2,apparent clearance, and apparent volume of distribut ion willbe reported.  
For miri kizumab, sparse sampling is conducted to obtain concentrations over the time course of 
the study ,which will be listed and summarized using descript ive statist ics.  
[IP_ADDRESS]. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameter estimates of cocktail drugs will be evaluated to delineate the effects 
of drug interaction.  Midazo lam, warfarin, dextromethorphan, omepra zole, and caffeine 
administered in the absence of mirikizumab will represent the reference treatments and will be 
analyzed separately .  Each drug administered wi th mirikizumab will  represent the test treatments
and will be analyzed separately .For the pri mary  analysis, l og-transform ed C maxand AUC(0 -∞)
estimates will be evaluated in a linear mixed -effects analysis of variance model wit h a fixed 
effect for treatment and a random effect for patient.  The treatment differences will be 
back-transformed to deriveratios of  geom etric least squares means and the corresponding 90% 
CIs. The MR and AUC (0-tlast)will also be analyzed using thismethod.
The t maxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the median difference 
based on the observ ed m edians, 90% CI, and p -values will be calculated.
[IP_ADDRESS]. Pharmacokinetic Exploratory Analyses
The same model used for the primary  PK analysis will be applied to the subgroups of responders 
to mirikizumab and nonresponders .  
A responder to mirikizumab will be d efined as a pat ient with 
ansPGA equal  to 0 or 1 at Day 116in Period 2.  A nonresponder will be defined as a patient 
withsPGA >[ADDRESS_63334] squares means and the corresponding 
90% CIs.
10.3.2. Safety Analyses
[IP_ADDRESS]. Clinical Evaluation of Safety
All study  treatm entand protoc ol procedure AEs will be listed and,if the frequency o f events 
allows, will be summarized using descript ive methodol ogy.
The inc idence of symptoms for each treatment will be presented by  [CONTACT_57992].  Symptoms reported to occur prior to study 
treatm entwill be distinguished fro m those reported as new or increased in severit y during the 
study.  Each symptom will be classified by [CONTACT_57993] m the medical  regulatory  
dictionary.
The number of study  treatm ent-related SAEs will be reported.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63335] ics.  Urinalysis data will be listed.  Electrocardiograms and physical examinat ions will be 
perform ed for saf ety monitoring purposes and will not be presented.  Addit ional analysis wil l be 
perform ed if warranted upon review of the data.
10.3.3. Immunogenicity Analyses
Treatment -emergent ADAs are defined as those with a titer 2- fold (1 dilution) greater than the 
minimum required dilut ion if no ADAs were detected at baseline (treatment -induced AD A) or 
those wi th a 4-fold (2 dilutions) increase in titer compared to baseline if ADAs were detected at 
baseline (treatment -boosted ADA).  
The frequency and percentage of patients with preexist ing ADAs and wit hTE ADA+ to 
mirikizumab will be listed and su mmarized .  The frequency of neutralizing ant ibodies will also 
be tabulated for TE ADA+ pat ients.
The rel ationship between the presence of ant ibodies and the PK parameters and other response s, 
including safet y and efficacy  to mirikizumab, maybe assessed.
10.3.4. Exploratory Analyses
[IP_ADDRESS]. Efficacy Assessments
The PASI scores, sPGA responses, and percent BSA evaluat ion results will be listed and 
summarized.  The proportion of pat ients who achieved sPGA (0, 1 ) and sPGA (0), and PASI 75, 
PASI 90, and PASI 100 (at least a 75 %, 90%, and 100% improvement from baseline in PASI 
score, respectively) will be summarized over time using descript ive statist ics.  The change fro m 
baseline in percent BSA will also be summarized over time using descript ive statist ics.
[IP_ADDRESS]. Biomarker Analyses
Concentrations of IL-19and change sfrom baseline will be listed and summarized by  [INVESTIGATOR_24258].  
10.3.5. Interim Analyses
An interim analysis may be performed after allenrolled subjects have co mpleted the outpati ent 
visit and PK sample co llection on Day 120 in Peri od2.  The purpose of this interim analysis is to 
provi de PK results to support a regulatory  submissio n.  No changes to the study  design are 
planned.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 55
LY307482811. References
[APA] American Psychiatric Associat ion.Diagnostic and statistical manual of mental disorders .
5thed. Washington ,DC: American Psychiatric Association ; 2013.
Blanchard J, Sawers SJ. The abso lute bioavailability  of caffeine in man. Eur J Clin Pharmacol . 
1983;24(1):93 -
98.
[EMA ] European Medicines Agency. Committee for medicinal products for human use (CHMP). 
Guideline on clinical invest igation of medicinal products indicated for the treatment of 
psori asis. CHMP/EWP/2454/02 corr. November 2004.
[
EMA ] European Medicines Agency. Guideline on the investigatio n of drug interactions. 
CPMP/EWP/560/95/Rev. 1 Corr 2**. June 2012.
[FDA] [LOCATION_002] Food and Drug Administration. Center for Drug Evaluation and Research. 
Clinical Drug Interaction Studies -Study  Design, Data Analysis, and Clinical Implicat ions. 
Guidance for Industry . October 2017.
Fredri ksson T, Pettersson U. Severe psoriasis -oral therapy  with a new retinoi d. Dermatologica.
1978;157(4):[ADDRESS_63336] ion potential of pazopanib, an oral vascular endothelial growth factor receptor ty rosine 
kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in pat ients with advanced so lid 
tumors. Clin Pha rmacol Ther . 2010;88(5):652 -659.
[HMA] Heads o f Medicines Agency. Public Assessment Report Scientific Discussio n 
Omeprazo l “Copyfarm” Omeprazo le. DK/H/1650/001- 003/MR . April 2009. Available at:  
http://www.hma.eu/fileadmin/dateien/pi[INVESTIGATOR_57967]/dk1650/parmod5_dk16 50om eprazo lcopyfarm.pdf
Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr. Maribavir pharmacokinetics and the 
effects of mult iple –dose m aribavi r on cy tochrom e P450 (CYP) 1A2, CYP 2C9, CYP 2C19, 
CYP 2D6, CYP 3A, N -acetyltransferase -2, and xanthine o xidase in healt hy adults. Antimicrob 
Agents Chemother . 2006;50(4):1130
-1135.
Menter A, Gottlieb A, Feldman SR, VanVoorhees AS, Leonardi CL, Gordon KB, Lebwohl M, 
Koo JYM, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines o f care for the 
management of psori asis and psori atic arthrit is: section 1. Overview of psoriasis and 
guidelines o f care for the treatment of psoriasis wit h bio logics. J Am Acad Dermatol . 
2008;58(5):826 -850.
National Psoriasis Foundat ion. The Psori asis and Psori atic Arthri tis Pocket Guide. Portland, OR ;
2009.
[PMDA] Pharmaceut icals Medical Devices Agency .Draft Gui deline on Drug Interactions. 2013.
Puig L. PASI90 response: the new standard in therapeutic efficacy  for psori asis. J Eur Acad 
Dermatol Venereol . 2015;29(4):[ADDRESS_63337] coefficient of variat ion in 
bioequivalence studies. Int J Clin Pharmacol Ther . 1995;33(8):427 -430. 
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 56
LY3074828Turpault S, B rian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X. 
Pharmacokinet ic assessment of a five -probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. 
Br J Clin Pharmacol . 2009;68(6):928 -935.
Wang J, Wang YM, Ahn HY. Bio logical products for the treatm ent of  psori asis: therapeutic 
targets, pharmacodynamics and disease -drug-drug interact ion implicat ions. AAPS J . 
2014;16(5):938 -947.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 57
LY3074828Appendix 1. Abbreviations and Definitions
Term Definition
ADA antidrug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory findin g), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve from zero to infinity
AUC([ADDRESS_63338]) area under the concentration versus time curve from time zero to the last time point with a 
measurable concentration
BCG Bacillus Calmette -Guerin
BP blood pressure
BSA body surface area
CI confidence interval
Cmax maximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory  requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by [CONTACT_57994].  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP clinical pharmacologist
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 58
LY3074828CRP clinical research physician:  Individual respon sible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, c linical research scientist, 
global safety physician ,or other medical officer.
CRU clinical research unit
C-SSRS Columbia -Suicide Severity Rating Scale
CV coefficient of variation
CYP cytochrome P450
ECG electrocardiogram
eCRF electronic case report form
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the study are 
those who have been assigned to a treatment.
enter Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
GCP good clinical practice
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Co uncil forHarmoni sation
informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate in a 
particular study , after having been informed of all aspects of the study that are relevant to 
the patient ’sdecision to participate.  Informed consent is documented by [CONTACT_3553] a 
written, signed and dated informed consent form.  
IL interleukin
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical study , including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
market ed products used for an unauthorized indication, or marketed products used to gain 
further information about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 59
LY3074828IV intravenous
MR metabolic ratio
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PASI Psoriasis Area Severity Inde x
PFS prefilled syringe
PK pharmacokinetic (s)
[COMPANY_003] purified protein derivat ive
PUVA psoralen and ultraviolet A
QIDS -SR16 Quick Inventory of Depressive Symptomatology -Self Report (16 items)
SAE serious adverse event
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
sPGA static Physicians Global Assessment
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
t1/2 half-life associated with the terminal rate constant in noncompartmental analysis
TB tuberculosis
TBL total bilirubin level
TE ADA treatment -emergent antidrug antibody
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment .
Th T helper
tmax time of maximum observed drug concentration
UC ulcerative colitis
ULN upper limit of normal
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 60
LY3074828Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology a Clinical chemistry a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate 
Mean cell volume Chloride
Mean cell hemoglobin Phospho rus
Mean cell hemoglobin concentration Glucose random
Leukocytes (WBC) Blood urea nitrogen (BUN)
Platelets Uric acid
Absolute counts of: Total cholesterol
Neutrophils Total protein
Lymphocy tes Albumin
Monocytes Total bilirubin
Eosinophils Alkaline phosphatase (ALP)
Basophils Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Urinaly sisa Creatinine
Specific gravity Gamma -glutamyl transferase (GGT )
pH
Protein Additional tests a
Glucose Ethanol testing b
Ketones Urine drug screen b
Bilirubin [COMPANY_003]/QuantiFERON -TB Gold/T -SPOT c
Urobilinogen Hepatitis C antibody c
Blood Hepatitis B core antibody (HBcAb+) c
Nitrite Hepatitis B surface antigen c
Urine leukocyte esterase Hepatitis B virus DNA
Microscopic examination of sediment d HIV c
Pregnancy test (females, as appropriate) e
FSH (females, as appropriate) c
Coagulation parameters a
PT(INR )
Abbreviations:  FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; INR = international 
normalized ratio; [COMPANY_003] = purified protein derivative; PT =prothrombin time; RBC = red blood cells; TB = 
tuberculosis; WBC = w hite blood cells.
aResults will be validated by [CONTACT_57995] .  Screening tests, pregnancy 
tests, and ethanol and drug screen performed locally; all other tests performed at central laboratory.
bUrine drug screen and ethanol level may be repeated prior to admission to the clinical research unit and at other 
times i ndicated in the Schedule of Activities (Section 2).  
cPerformed at screening only.
dTest only if dipstick result is abnormal.  
eSerum pregnancy test to be performed at screening for all females .  Serum o r urine pregnancy test willbe 
performed locally at all other times for females of childbearing potential .Additional tests may be performed at 
the discretion of the investigator.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63339] igator is responsible for:
ensuring that the patient understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipation is vo luntary.
ensuring that informed consent is given by [CONTACT_57996].  This 
includes obtaining the appropriate signatures and dates on the informed consent form 
(ICF) prior to the performance of any  protocol  procedures and pri or to the administration 
of investigational product.
answering any quest ions the pati ent m ay have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the patient ’swillingness to 
continue his or her participat ionin the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for pati ents.  Individual 
investigators may have addit ional local requirements or processes.   Study -specific recruit ment 
materi al should be approved by [CONTACT_11007] .
Ethical Review
The invest igator or appropriate local representative must give assurance that the ethical review 
board (ERB) was properly const ituted and convened as required by [CONTACT_57997] (ICH) guidelines and other applicable laws and regulat ions.
Docum entati on of  ERB approval  of the protocol and the ICF m ustbe provided to Lilly before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on good clinical practice ( GCP ) .
The study  site’s ERB(s) shoul d be provi ded wi th the f ollowing:
the current mirikizumab Invest igator’s Brochure , drug cocktail package inserts, and 
updates during the course of the study
ICF
relevant curri cula vi tae
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 62
LY3074828Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with :
1)consensus ethics principles derived fro m internat ional ethics guidelines, including the 
Declaration of Helsinki and Council for International Or ganizat ions of Medical Sciences
International Ethical Guidelines 
2)applicable ICH GCP Guide lines 
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Final Report Signature
[CONTACT_58003] , indicat ing agreement t hat, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The invest igator with the most enrolled pat ients will serve as the final report coordinat ing 
investigator.  If this investigator is unable to fu lfill this function, another invest igator will be 
chosen by [CONTACT_57998].
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
Provide instructi onal material to the study  sites, as appropriate.
Provide training to instruct the invest igators and study coordinators.  This training will 
give instruction on the protocol, the complet ion of the electronic case report forms 
(eCRFs ), and study  procedures.
Make peri odic visi ts to the study  site.
Be available for consultation and stay  in contact [CONTACT_57999] h the study  site personnel  by [CONTACT_2319] , 
telephone, and/or fax.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 63
LY3074828Review and evaluate eCRF data and/or use standard computer edits to detect errors in 
data collect ion.
Conduct a qualit y review of the database .
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47557]/or 
regul atory  agencies at an y time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The si te must define and retain all 
source re cords and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of patient personal information co llected will be provided in a written 
docum ent to the patient by  [CONTACT_456] .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page [ADDRESS_63340] Alkaline phosphatase isoenzymes a
GGT
CPK Anti -smooth muscle antibody (or anti -actin antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate am inotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 65
LY3074828Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es, and bioanaly tical assays) during the study .  
Protocol I6T-MC -AMBP Sampling Summary
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volum e 
(mL)
Screening tests a 36 1 36
Clinical laboratory tests a 16 10 160
Pharmacokinetics :
Midazolam and 1 ’-hydroxy midazolam [ADDRESS_63341] 10 mL 590
aAdditional samples may be drawn if needed for safety purposes.
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 66
LY3074828Appendix 6. Protocol A mendment I6T-MC-AMBP(a)
Summary  Evaluation of the Effect of Mirikizumab on the 
Pharmacokinetics of Cy tochrome P450 Substrates in 
Patients with Moderate -to-Severe Plaque Psoriasis
Overview
Protocol  I6T-MC-AMBP Evaluat ion of the Effect of Mirikizumab on the Pharmacokinetics of 
Cytochrom e P450 Substrates in Patients with Mode rate-to-Severe Plaque Psori asishas been 
amended.  The new protocol is indicated by  [CONTACT_58000] (a ) and will be used to conduct the 
study  in place of any preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are as fo llows:
In Secti on 7.1, a dosing volume error for midazolam has been corrected.  T he 
administered midazolam volumehas been updated to 0.5 mL to achieve a 1-mg 
midazo lamdose from 2mg/mLmidazo la
m syrup.  
In the Study  Schedule for Peri od 2 (Secti on 2), an error in the footnote l etter desi gnati ons 
within the table has been corrected.  T he footnote for mirikizumab PK samples has been 
updated from “g” to “h” .  
I6T-MC-AMBP (a)Clinical Pharmacology Protocol Page 67
LY3074828Revised Protocol Sections
Note: All deletions have been ident ified by [CONTACT_58001] .
All additions have been ident ified by [CONTACT_58002] .
2. Schedule of Activities
Study Schedule Protocol I6T-MC -AMBP –Period 2
PK Samples (hours)
Mirikizumab h g Predose Predose Predose Predose Predose Predose X
7.1. Treatment Administered
The 1 -mg oral dose will be administered as 0.1 0.5 mL of 2 -mg/mL co mmercially available midazo lam syrup.
Leo Document ID = 96c8d19e-cd1d-4e20-b25c-5cb9c555c304
Approver: 
Approval Date & Time: 09-Aug-2018 23:02:56 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 09-Aug-2018 23:02:56 GMT
Signature [CONTACT_32869]: Approved
